DDInter223 DDInter255
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Bosentan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Bosentan {u} (Compound) causes {v} (Side Effect) Sinusitis
Sinusitis {u} (Side Effect) is caused by {v} (Compound) Busulfan
Bosentan {u} (Compound) binds {v} (Gene) EDNRB
EDNRB {u} (Gene) regulates {v} (Gene) LSM6
LSM6 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Bosentan {u} (Compound) downregulates {v} (Gene) PSMB8
PSMB8 {u} (Gene) regulates {v} (Gene) CCND3
CCND3 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Bosentan {u} (Compound) binds {v} (Gene) EDNRB
EDNRB {u} (Gene) is upregulated by {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Bosentan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Bosentan {u} (Compound) downregulates {v} (Gene) PSMB8
PSMB8 {u} (Gene) is regulated by {v} (Gene) SSBP2
SSBP2 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Bosentan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Bosentan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Busulfan
Bosentan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) MGST2
MGST2 {u} (Gene) is bound by {v} (Compound) Busulfan
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Bosentan (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Busulfan (Compound)
Bosentan (Compound) binds EDNRB (Gene) and EDNRB (Gene) regulates LSM6 (Gene) and LSM6 (Gene) is downregulated by Busulfan (Compound)
Bosentan (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) regulates CCND3 (Gene) and CCND3 (Gene) is downregulated by Busulfan (Compound)
Bosentan (Compound) binds EDNRB (Gene) and EDNRB (Gene) is upregulated by hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Bosentan may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Bosentan (Compound) downregulates PSMB8 (Gene) and PSMB8 (Gene) is regulated by SSBP2 (Gene) and SSBP2 (Gene) is upregulated by Busulfan (Compound)
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Bosentan may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Busulfan (Compound)
Bosentan may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) downregulates MGST2 (Gene) and MGST2 (Gene) is bound by Busulfan (Compound)